Insider Transactions

Klinger Shannon Thyme

Chief Legal Officer

In the last 12 months, Klinger Shannon Thyme filed 58 SEC Form 4 transactions across 1 issuer — $0 in open-market purchases and $899.6K in open-market sales. 5% of these transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.

Issuers Filed For By open-market buy volume

Recent Form 4 Filings Most recent 58 of 58 (1-year window)

Date Ticker Company Type SEC Code Value Shares Price
2026-06-05 MRNA Moderna, Inc. Exercise M $0 11,798
2026-06-05 MRNA Moderna, Inc. Exercise M $0 11,798 $0.00
2026-06-05 MRNA Moderna, Inc. Other F $294.3K 5,705 $51.59
2026-06-04 MRNA Moderna, Inc. Exercise 10b5-1 M $107.5K 3,471 $30.96
2026-06-04 MRNA Moderna, Inc. Exercise 10b5-1 M $0 3,471 $0.00
2026-06-04 MRNA Moderna, Inc. Sell 10b5-1 S $173.6K 3,471 $50.00
2026-06-01 MRNA Moderna, Inc. Exercise M $0 2,165
2026-06-01 MRNA Moderna, Inc. Exercise M $0 2,165 $0.00
2026-06-01 MRNA Moderna, Inc. Other F $49.4K 1,047 $47.19
2026-05-28 MRNA Moderna, Inc. Exercise M $0 328
2026-05-28 MRNA Moderna, Inc. Exercise M $0 328 $0.00
2026-05-28 MRNA Moderna, Inc. Other F $7.6K 159 $47.61
2026-05-27 MRNA Moderna, Inc. Exercise M $0 773
2026-05-27 MRNA Moderna, Inc. Exercise M $0 773 $0.00
2026-05-27 MRNA Moderna, Inc. Other F $17.6K 374 $47.03
2026-03-05 MRNA Moderna, Inc. Grant $0 11,797
2026-03-05 MRNA Moderna, Inc. Grant $329.7K 5,704 $57.80
2026-03-05 MRNA Moderna, Inc. Grant $0 11,797 $0.00
2026-03-02 MRNA Moderna, Inc. Grant $429.9K 13,885 $30.96
2026-03-02 MRNA Moderna, Inc. Grant $0 13,885 $0.00
2026-03-02 MRNA Moderna, Inc. Sell $726.0K 13,885 $52.29
2026-03-01 MRNA Moderna, Inc. Grant $0 29,275 $0.00
2026-03-01 MRNA Moderna, Inc. Grant $0 38,553 $0.00
2026-02-27 MRNA Moderna, Inc. Grant $0 233
2026-02-27 MRNA Moderna, Inc. Grant $5.8K 113 $51.71
2026-02-27 MRNA Moderna, Inc. Grant $0 329
2026-02-27 MRNA Moderna, Inc. Grant $8.3K 160 $51.71
2026-02-27 MRNA Moderna, Inc. Grant $0 774
2026-02-27 MRNA Moderna, Inc. Grant $19.4K 375 $51.71
2026-02-27 MRNA Moderna, Inc. Grant $0 8,663
2026-02-27 MRNA Moderna, Inc. Grant $216.6K 4,189 $51.71
2026-02-27 MRNA Moderna, Inc. Grant $0 233 $0.00
2026-02-27 MRNA Moderna, Inc. Grant $0 329 $0.00
2026-02-27 MRNA Moderna, Inc. Grant $0 774 $0.00
2026-02-27 MRNA Moderna, Inc. Grant $0 8,663 $0.00
2026-02-11 MRNA Moderna, Inc. Grant $0 2,630 $0.00
2026-02-11 MRNA Moderna, Inc. Grant $56.0K 1,334 $41.99
2025-12-05 MRNA Moderna, Inc. Grant $0 47,190
2025-12-05 MRNA Moderna, Inc. Grant $581.6K 22,817 $25.49
2025-12-05 MRNA Moderna, Inc. Grant $0 47,190 $0.00
2025-12-01 MRNA Moderna, Inc. Grant $0 233
2025-12-01 MRNA Moderna, Inc. Grant $2.9K 113 $25.98
2025-12-01 MRNA Moderna, Inc. Grant $0 233 $0.00
2025-11-28 MRNA Moderna, Inc. Grant $0 329
2025-11-28 MRNA Moderna, Inc. Grant $4.0K 160 $25.01
2025-11-28 MRNA Moderna, Inc. Grant $0 329 $0.00
2025-11-26 MRNA Moderna, Inc. Grant $0 773
2025-11-26 MRNA Moderna, Inc. Grant $9.3K 374 $24.75
2025-11-26 MRNA Moderna, Inc. Grant $0 773 $0.00
2025-08-29 MRNA Moderna, Inc. Grant $0 232
2025-08-29 MRNA Moderna, Inc. Grant $2.8K 113 $24.47
2025-08-29 MRNA Moderna, Inc. Grant $0 232 $0.00
2025-08-28 MRNA Moderna, Inc. Grant $0 329
2025-08-28 MRNA Moderna, Inc. Grant $4.0K 160 $25.10
2025-08-28 MRNA Moderna, Inc. Grant $0 329 $0.00
2025-08-27 MRNA Moderna, Inc. Grant $0 774
2025-08-27 MRNA Moderna, Inc. Grant $9.3K 375 $24.73
2025-08-27 MRNA Moderna, Inc. Grant $0 774 $0.00

Methodology & FAQ

How These Filings Are Sourced

All transactions on this page are sourced directly from SEC EDGAR. A complete description of the open-market vs grant distinction, the Rule 10b5-1 plan-reference heuristic, and the per-insider name matching is documented in the Methodology.

What companies does Klinger Shannon Thyme file Form 4 disclosures for?

Klinger Shannon Thyme has filed SEC Form 4 transactions for 1 issuer in the last 12 months: Moderna, Inc. (MRNA).

What does the 10b5-1 badge mean on these transactions?

Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Of Klinger Shannon Thyme's 58 reported transactions in the last 12 months, 3 (5%) reference a 10b5-1 trading plan in the Form 4 footnotes.

Are these all the transactions Klinger Shannon Thyme has executed?

This page shows SEC Form 4 transactions on record in Pactolio's tracked universe for the last 12 months. Form 4 only covers transactions in registered classes of equity at issuers where the person qualifies as an insider (officer, director, or 10% beneficial owner). Trades in funds, foreign issuers, or non-insider positions are not disclosed under Form 4 and are not included here.